QUANTICA
10.11.2022 11:46:41 CET | Business Wire | Press release
Last November at the international additive manufacturing exhibition Formnext, Quantica announced its T1 Pro, an R&D system that showcased the company’s multi-material, ultra-high viscosity jetting capabilities, known as NovoJet™. A year later, Quantica is back at the Frankfurt-based expo, this time introducing a new Desktop system– the NovoJet™ C-7.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005047/en/
The Berlin-based 3D printing start-up is pushing the boundaries of multi-material and high-performance material jetting, through the introduction of the NovoJet™ C-7. A printer suitable for research, feasibility studies, and small scale production of custom applications. It will be made available to research institutes and industry partners, looking to develop high-performance, multi-material 3D printing and other additive manufacturing applications.
NovoJet™ C-7 is an open printing platform, ideal for 2D and 3D application development using Quantica’s ultra-high viscosity jetting technology. It has been created for research institutes, R&D labs, and organizations looking to develop new additive manufacturing materials and workflows. Beyond feasibility testing and application development, the printer can also be used for customized and low-volume production, enabling a truly seamless transition from lab to production.
Key features of the NovoJet™ C-7 include:
- Material Experimentation: The system uses printheads capable of handling a wide range of fluids with viscosities exceeding 380mPa•s at jetting temperature, equating to approximately 4000mPa•s at ambient temperature. Along with experimentation with liquids with high particle loading.
- New Material Combinations: The system has the ability to control up to 7 material channels giving users access to new material combinations with better mechanical properties, color fidelity, and aesthetics.
- System Customization: The system offers customizable integrations for research and development needs.
The power of Quantica’s NovoJet™ printhead technology is its ability to print materials that are 15 times more viscous than legacy inkjet printheads. This opens up new possibilities for delivering high value end-part products with properties such as high toughness, temperature resistance, conductivity, biocompatibility, and flexibility manufactured in a single process.
Multiple industry partners, mainly within the dental, medical and electronics space, have started collaborations with Quantica to develop targeted solutions based on the novel capabilities.
“This new system unlocks enormous possibilities for the material deposition industries, giving material developers the ability to move past the limitations of low performance fluids and start developing new formulations with better properties of interest. In the end, we empower organizations to build products in new and exciting ways,” said Ramon Borrell, CTO of Quantica. “Quantica is already exploring several applications in the dental, healthcare, consumer goods, and electronics industries. We are excited to support these, and the many other, industries in breaking down current inkjet barriers and limitations.”
For more information about the NovoJet™ C-7, please visit https://quantica3d.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom